News & Updates

MS patients on certain DMTs may have limited protection from COVID-19 vax
MS patients on certain DMTs may have limited protection from COVID-19 vax
30 May 2022 byRoshini Claire Anthony

The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.

MS patients on certain DMTs may have limited protection from COVID-19 vax
30 May 2022
COVID-19 jabs help reduce long-term symptoms
COVID-19 jabs help reduce long-term symptoms
27 May 2022 byStephen Padilla

COVID-19 vaccination appears to reduce the odds of long COVID symptoms, with continuous improvement following a second dose, at least in the first few months after the shot, suggests a study.

COVID-19 jabs help reduce long-term symptoms
27 May 2022
Infants with late-onset GBS develop sepsis, meningitis
Infants with late-onset GBS develop sepsis, meningitis
27 May 2022

Sepsis or septic shock and bacterial meningitis, which are associated with non-negligible morbidity and mortality, frequently occur in infants with group B Streptococcus (GBS) late-onset disease (LOD), reports a recent study.

Infants with late-onset GBS develop sepsis, meningitis
27 May 2022
Tuberculosis common in CKD patients
Tuberculosis common in CKD patients
27 May 2022